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Summary 
The apparent affinity of naloxone at cerebral and spinal 
sites was estimated using selective mu [D-AIa 2 , Gly-ol5] - 
enkephalin (DAGO) and delta [D-Pen 2 , D-Pen5]enkephalin] 
(DPDPE) opioid agonists in the mouse warm water tail-withdrawal 
test in vivo; the mu agonist morphine was employed as a reference 
compound. The approach was to determine the naloxone pA 2 using 
a time-dependent method with both agonist and antagonist given 
intracerebroventricularly (i.c.v.) or intrathecally (i.th.); 
naloxone was always given 5 min before the agonist. Complete 
time-response curves were determined for each agonist at each 
site in the absence, and in the presence, of a single, fixed 
i.c.v, or i.th. dose of naloxone. From these i.c.v, or i.th. 
pairs of time-response curves, pairs of dose-response lines were 
constructed at various times; these lines showed decreasing 
displacement with time, indicative of the disappearance of 
naloxone. The graph of log (dose ratio - i) vs. time was linear 
with negative slope, in agreement with the time-dependent form of 
the equation for competitive antagonism. From this plot, the 
apparent pA 2 and naloxone half-life was calculated at each site 
and against each agonist. The affinity of naloxone was not 
significantly different when compared between agonlsts after 
i.c.v, administration. A small difference was seen between the 
affinity of i.th. naloxone against DPDPE and DAGO; the i.th. 
naloxone pA 2 against morphine, however, was not different than 
that for DPDPE and DAGO. The naloxone half-life varied between 
6.6 and 16.9 min, values close to those previously reported for 
this compound. These results suggest that the agonists studied 
may produce their i.c.v, analgesic effects at the same receptor 
type or that alternatively, the naloxone pA 2 may be 
fortuitously similar for mu and delta receptors in vivo. 
Additionally, while the affinity of naloxone appears different 
for the receptors activated by i.th. DAGO and DPDPE, further work 
may be necessary before firm conclusions regarding the nature of 
the spinal analgesic receptor(s) can be drawn. 
Recent work in this laboratory (1,2) and that of others (3,4) has attempted 
to investigate the role of central delta opioid receptors in various opioid 
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mediated effects such as analgesia, slowing of gastrointestinal propulsion, 
production of respiratory depression and induction of dependence. These 
studies have employed the most selective agonists presently available for mu 
(DAGO)(5) and delta (DPDPE)(6) opioid receptors. The development of selective 
agonists such as DPDPE has finally begun to allow some insights as to the 
physiological function of these receptors. Questions regarding the role of 
delta receptors have remained, however, since even selective agonists such as 
DPDPE may produce their opioid effects at other (mu?) types of receptors. 
A traditional approach in the differentiation of receptors has been the 
determination of antagonist affinity against various agonists. This approach 
was extensively and successfully employed in opioid research by Takemori and 
his colleagues both in vitro (7) and in vivo (8,9). The method involves 
determination of the agonist dose-response relationship in the absence and in 
the presence of several doses of antagonist. The resulting dose ratios are 
then used in the construction of a Schild plot (i0) from which the antagonist 
affinity is determined (see ii, for review). Application of this method in 
vivo, however, presents some special problems since the administered doses of 
agonist and antagonist are used in the calculation with the assumption that 
these doses are proportional to the tissue concentration. Further, the tissue 
concentration is assumed to be maximal at the time of peak effect and the 
measurement of effect must be made at this time. As there may be a 
dose-related time to peak effect, it is often difficult, if not impossible, to 
make the measurement of effect at the appropriate time for each dose. These 
factors are among those which make difficult the interpretation of pA 2 
values obtained with studies in vivo. Additionally, a more practical 
difficulty arises from the quantity of agonist needed to determine the 
dose-ratios necessary for construction of the Schild plot. While this concern 
is not normally important, the availability of some peptides, such as DPDPE, 
has been limited. 
The present investigation attempts to determine whether naloxone has 
similar affinity at cerebral and spinal opioid receptors activated by the 
delta agonist, DPDPE, or the mu agonists morphine and DAGO. A variation of 
the traditional pA 2 method has been employed. This method includes time as 
a variable and thus obviates many of the concerns of pA 2 studies in vivo, 
such as the making of measurements at the time of peak effect and the 
assumption of equilibrium conditions. This method has been previously derived 
(12) and validated (13). Additionally, the present study administered both 
the agonist and the antagonist into the central nervous system. 
Administration of compounds by these routes improves precision by delivering 
compounds close to their loci of action thereby permitting a dose unit more 
closely approximating tissue concentration as well as more predictable 
pharmacokinetics. We now report that the naloxone pA 2 against mu (DAGO, 
morphine) and delta (DPDPE) agonists is not significantly different after 
i.c.v, administration of these compounds. A small difference in the naloxone 
pA 2 was seen against DAGO and DPDPE after i.th. administration. 
Additionally, the half-life of naloxone (and 95% confidence limits) was 
determined as a by-product of the calculations, and this value was found to be 
similar to those previously reported. 
Methods 
Mouse warm-water tail-withdrawal test 
Experiments were made using male, ICR mice (25-30 g). The animals were 
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housed in groups of 5 in a temperature controlled room with a 12 hr light-dark 
cycle (lights on at 7.00 AM). Food and water were continuously available. On 
the day of the experiment, each mouse was tested for a control response to a 
noxious stimulus. The tail was immersed in warm water (55°C) and the time 
to a rapid flick determined. Groups of mice then received an i.c.v, or i.th. 
injection of saline or naloxone, followed after 5 min by a dose of i.c.v. (in 
the same ventricle) or i.th. agonist. Testing took place after a further 5, 
i0, 20, 40, 60, 80, i00, and 120 min. Each response latency was then compared 
to the individual control latency and percent analgesia for each mouse 
expressed as: 
% analgesia = i00 x (test latency - control latency)/(15 - control 
latency), with 15 sec chosen as the maximum time for tail-withdrawal. Animals 
not removing their tails within 15 sec were scored as having 100% analgesia. 
Theory 
The time-dependent form of the equation for competitive antagonism was 
employed as previously derived by Tallarida and associates (12). Briefly, the 
dissociation constant (K B) of a competitive antagonist of concentration B is 
computed by the equation of Arunlakshana and Schild (14): 
log (A'/A - i) = log (B) - log KB, where A' and A are equieffectlve 
agonist concentrations in the presence and in the absence of the antagonist. 
Although the determination of antagonist affinity can be made directly from 
the above equation, a standard approach is to determine the dose ratio in the 
presence of several concentrations of antagonist and to plot log (dose ratio - 
i) vs. log B (the Schild plot). This plot is theoretically linear with slope 
equal to 1 and intercept equal to -log K B (ordinate), or pA 2 
(abscissa)(14). A modification of the above equation which considers time 
assumes that both agonlst and antagonist concentration decrease exponentially 
after reaching maximum concentration has been achieved. Thus, A = Aoe -at, 
and B = Boe -bt, where A o and B o are the maximum concentrations 
(assumed proportional to the administered concentrations), a and b are the 
rate constants for the disappearance of A and B, respectively and t is the 
time after peak effect. Thus, t = 0 corresponds to the time of peak effect. 
From these, the time dependent form of the Arunlakshana and Schild equation is: 
log (A'/A - i) = log B o - blog (e)t - log K B. If log (A'/A - i) is 
plotted against time, a straight line results of slope = -blog (e) and 
intercept = (log B - log KB). As pA 2 = -log KB, then pA 2 = intercept 
-log B o. Additionally, the rate constant, b, for the disappearance of the 
antagonist, and resulting half-life, follows. It should be pointed out that 
by using the time-dependent method one does not need to make assumptions 
regarding the time of peak effect of the agonist and the agonist plus 
antagonist. This consideration increases the suitability of this approach for 
study in vivo. 
Statistics 
All dose-response lines were constructed by standard regression techniques 
as described by Tallarida and Murray (15). Dose-ratlos were determined by 
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establishing the best parallel regression lines in the absence and in the 
presence of all naloxone doses. The 95% confidence limits for the pA 2 value 
of each agonist and route were estimated from the error of the intercept on 
the ordinate; thus, the 95% C.L. was "t" times the standard error of the 
intercept, where "t" represents the area under the t-distribution curve based 
on the size of the sample. The 95% C.L. of the naloxone half-life was 
similarly determined from the confidence limits of the slope of the regression 
line obtained when plotting log (dose ratio - i) vs. time. 
Results 
Time-response curves for morphine, DAGO and DPDPE in the absence (top row) 
and in the presence (bottom row) of a single i.c.v, dose of naloxone (0.5, 0.5 
and 1 ug, respectively) are shown in Fig. 1 and for a single i.th. dose of 
naloxone (I, 0.5 and 0.i ug) are shown in Fig. 2. The agonists showed a 
duration of action after i.c.v, or i.th. administration ranging between 80 and 
i00 min. From these paired curves, the response in the absence, and in the 
presence, of naloxone was plotted at each dose of agonist at various times. 
An example of such a plot for i.c.v. DPDPE is shown at 20, 25, 35 and 40 min 
in Fig. 3. These plots for other agonists and routes were similar, showing a 
decrease in dose-ratio with time, indicative of the disappearance of 
naloxone. The log (dose ratio - I) obtained from plots such as those in 
Fig. 3 are shown for each agonist and route in Fig. 4. Each of the lines 
showed excellent linear correlation, strongly supporting the validity of the 
theoretical assumptions. Note that the slopes of these lines (Fig. 4) do not 
reflect whether antagonism is competitive (as shown by a slope of unity in the 
traditional Schild plot) but are the result of the kinetics of naloxone 
disappearance from the biophase. From the plots in Fig. 4, the pA 2 (and 
corresponding 95% C.L.'s) were obtained from each agonist and route 
(Table I). Additionally, the naloxone half-life (and 95% C.L.'s) against each 
agonist and route (given by the slope of the lines in Fig. 4) is shown in 
Table I. Finally, the peak A50 (and 95% C.L.'s) obtained from the 
time-response curves in the absence of naloxone (Fig. 1,2) are also shown in 
Table I. 
The apparent naloxone pA 2 values for i.c.v, morphine, DAGO and DPDPE 
were 10.39 (10.29 - 10.96), 9.99 (9.28 - 10.69) and 10.63 (10.14 - 10.64), 
respectively. Similarly, after i.th. administration of morphine, DAGO and 
DPDPE, the pA 2 values were 10.16 (9.91 - 10.43), 9.74 (9.5 - 9.98) and 10.15 
(10.12 - 10.18), respectively. The overlapping 95% C.L.'s after i.c.v. 
administration indicate a lack of significant difference between these values 
when compared between agonists. The values seen after i.th. administration 
indicate no overlap between the naloxone pA 2 against DAGO and DPDPE, 
although the value against morphine was not different from either of the other 
agonists. The half-life of naloxone was found to range approximately between 
9 and 17 min (see Table I), values that compare well with those previously 
reported by the same, and other techniques (13,16). An exception was the 
briefer naloxone half-life found with i.c.v, morphine (6.6 min). 
Additionally, a comparison of peak A50 values of each compound after i.c.v. 
and i.th. administration shows that morphine and DAGO are more potent i.c.v. 
(3.6 and 8.3 fold, respectively) while DPDPE is essentially equipotent by the 
two routes. 
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Figure i. Time-response curves for i.c.v, morphine, DAGO and DPDPE analgesia 
in the absence (top row) and in the presence (bottom row) of a single, i.c.v. 
dose of naloxone (0.5, 0.5 and 1 ~g, respectively) given 5 min prior to testing 
Testing took place 20 min after the agonist. Dose given is shown by the value 
next to each curve (ug/mouse) 
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Figure 2. Time-response curves for i.th. morphine, DAGO and DPDPE analgesia 
in the absence (top row) and in the presence (bottom row) of a single, i.th. 
dose of naloxone (i, 0.5 and 0.i ~g, respectively) given 5 min prior to testing 
Testing took place 20 min after the agonist (+i0 min for DPDPE). Dose given is 
shown by the value next to each curve (~g/mouse). 
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Figure 4. Plots of log (dose-ratio - I) vs. time for i,c.v. (left panel) and 
i . t h .  ( r i g h t  p a n e l )  m o r p h i n e ,  DAGO a n d  DPDPE i n  t h e  m o u s e  t a i l - w i t h d r a w a l  
test. See  t e x t  f o r  d e t a i l s .  
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TABLE I 
Time-dependent apparent pA 2 for naloxone against DAGO, morphine and DPDPE 
after i.c.v, or i.th. administration. Naloxone was given at - 5 min, agonists 
at t = 0~ and testing occurred at + 20 min for all compounds except i.th. 
DPDPE (+ i0 min) in the mouse warm water tail-immersion test. 
Agonist Route pA 2 (95% C.L.) tl/2 (95~ C.L.)(min) A50 (ug, peak) 
Morphine i.c.v. 10.39(10.14-10.64) 6.6 (5.6-7.9) 0.21(0.075-0.61) 
DAGO i.c.v. 9.99(9.28-10.69) 16.99(7.9-26.1) 0.005(0.003-0.007) 
DPDPE i.c.v. 10.63(10.29-10.96) 9.1 (6.4-16.1) 6.11(3.76-9.93) 
Morphine i.th. 10.16(9.91-10.43) 10.2 (7.4-16.3) 0.76(0.25-2.31) 
DAGO i.th. 9.74(9.50-9.98) 10.89(8.7-14.7) 0.042(0.03-0.06) 
DPDPE i.th. 10.15(10.12-10.18) 14.22(13.4-15) 5.2(4.08-6.67) 
Discussion 
The present study has determined the apparent pA 2 of naloxone against 
agonists selective for delta (DPDPE) and mu (DAGO) receptors, with morphine 
employed as a reference agonist. The approach involved the determination of 
this affinity constant at cerebral and spinal sites using a tlme-dependent 
method. Critically, both the agonist and the antagonist were given either 
into the brain or into the spinal subarachnoid space. In particular, 
administration of the antagonist close to its site of action increases the 
precision of the determination of affinity. The values obtained, however, are 
not directly comparable to studies using different routes of administration. 
It has been well established that values of pA 2 in vivo, are dependent on 
the route of compound administration (ii). It follows, therefore, that the 
values of the naloxone pA 2 reported after i.c.v, administration are not 
directly comparable to the values reported after i.th. naloxone. This 
conclusion is supported by the different tlme-response curves (Fig. i, 2). 
The time-dependent method was originally derived by Tallarida and 
colleagues (12) as a check on the standard method of Schild (10). The results 
were found to agree well with the traditional method in that study and in a 
subsequent validation of the method when naloxone was given by a central 
(i.c.v.) route (13). Our results indicate a lack of significant difference 
between the affinity of naloxone for the cerebral receptors activated by DPDPE 
and those activated by DAGO and morphine. A difference in naloxone affinity 
against these receptor selective agonists would be interpreted as suggesting 
that the agonlsts were acting at different receptor populations. Similar 
affinity suggests either that the agonists are activating the same receptor 
population, or that there is a fortuitous similarity in naloxone affinity at 
two different receptor populations. The present work cannot distinguish 
between these possibilities. It seems possible that the affinity of the 
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agonists for each receptor may be close enough that pA 2 determinations in 
vivo are unable to discriminate between them. Alternatively, the similarity 
in values argues that the i.c.v, analgesic receptor activated by DPDPE, 
morphine and DAGO are the same. It should be noted, however, that significant 
evidence indicates that DPDPE acts at receptors different from those acted 
upon by i.c.v, morphine. For example, Porreca et al. (i) have reported that 
while i.c.v, morphine and DAGO produce both analgesia and inhibition of 
gastrointestinal transit, i.c.v, administration of DPDPE results only in 
analgesia. In consequence, the lack of difference between the naloxone pA 2 
against morphine, DAGO and DPDPE is difficult to explain. 
An evaluation of the naloxone pA 2 values after spinal administration 
shows that the confidence limits of this antagonist against morphine overlap 
with those of DAGO and DPDPE. The affinity of naloxone appears to differ, 
however, between i.th. DPDPE and i.th. DAGO. The magnitude of this 
difference, however, is very small, and in our view, probably does not 
represent a meaningful difference. Thus, DPDPE and DAGO, the most selective 
agonists for the delta and mu receptors, respectively, may be acting at 
different spinal receptors in the production of analgesia. Caution should be 
exercised, however, as the confidence limits of the naloxone pA 2 against 
i.th. DPDPE are unusually small, due in part to the excellent fit of the log 
(dose ratio - i) vs. time plot. These unusually tight confidence limits may 
lead to incorrect conclusions. It should be noted, that the question of 
opioid receptor involvement in antinociception has been previously addressed 
using other approaches, especially at the level of the spinal cord. In 
particular, Yaksh and colleagues have addressed this issue in a series of work 
which has supported the separate involvement of spinal and supraspinal mu and 
delta receptors in antinociception. Tung and Yaksh (16) demonstrated 
different ~A 2 values for i.p. naloxone against i.th. ethylketocyclazocine 
and [D-AIa ~, D-Leu5]enkephalin (DADLE). Furthermore, in rats tolerant to 
morphine, that study showed no change in the i.th. DADLE dose-response curve. 
This conclusion was supported by the work of Tseng (17) who demonstrated only 
partial cross-tolerance between morphine and DADLE spinal anticociception in 
the rat. Additional work by Yaksh in the primate (18) using many approaches 
also concluded the involvement of both mu and delta receptors at the spinal 
level, a conclusion also supported in later work in the rat (19) which also 
suggested the involvement of spinal kappa receptors in visceral chemical, but 
not thermal, stimuli. Finally, very recent work (20) has demonstrated the 
involvement of supraspinal delta opioid receptors, in addition to mu 
receptors, in antinociception in tests utilizing heat as the nociceptive 
stimulus. Jensen and Yaksh (20) have reported that mu (morphine and 
sufentanil) and delta (DADLE, [D-Set 2 , Leu 5 , Thr6]enkephalin) agonists 
were effective in the tail flick test when given directly into the 
periaqueductal gray. In contrast, only the delta agonists were effective in 
this test when the compounds were given into the medullary reticular 
formation. Thus, the results of various approaches must be integrated before 
a final conclusion regarding the nature of the spinal analgesic receptor acted 
upon by DPDPE and DAGO or morphine can be drawn; the small difference in the 
naloxone pA 2 against DAGO and DPDPE can be evaluated only as one piece of 
evidence. 
This study provides an attempt to determine the nature of the analgesic 
effect of a highly selective agonist at the delta receptor. Additional 
information regarding the time-course for these agonists at different routes 
is also provided. It is interesting that the doses of naloxone necessary to 
provide intermediate levels of antagonism varied for each compound and for 
each route, with i.th. DPDPE being the most sensitive to antagonism (only 0.i 
ug naloxone necessary). The reasons for these differences in naloxone dose 
are unclear, but may relate to the pharmacokinetics of the compounds at the 
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spinal and supraspinal levels. Finally, the half-llfe of naloxone was 
relatively consistent with results reported by other methods (approximately 13 
- 20 min) (13,21). The naloxone half-life against i.c.v, morphine, however, 
was briefer than expected; the reasons for this are unclear. 
In summary, the present study demonstrates that within the limits of our 
methodology, the affinity of naloxone for mu and delta receptors as revealed 
by selective agonists (DAGO, DPDPE) is very similar. The results obtained 
using the i.th. route indicate the possibility of a small difference between 
the affinity of naloxone for the receptors activated by DPDPE and DAGO. The 
interpretation of this result is made difficult, however, due to (a) the small 
confidence limits of the i.th. naloxone-DPDPE pA 2 and, (b) the small 
difference in the absolute magnitude of the two affinity constants. Further 
work using selective antagonists is required to establish whether these 
agonists produce their analgesic effects at the same or separate receptors. 
Additionally, pharmacokinetic data have been established for i.c.v, and i.th. 
administration of these agonists, and morphine, in the absence and in the 
presence of naloxone. Such information may be useful in the design of future 
experimental protocols with these agonists. 
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